ODAN-SODIUM POLYSTYRENE SULFONATE 1 G
SODIUM POLYSTYRENE SULFONATE : 1 G · DIN 02473941 · ODAN LABORATORIES LTD
Health Canada status: MARKETED
What is ODAN-SODIUM POLYSTYRENE SULFONATE?
ODAN-SODIUM POLYSTYRENE SULFONATE 1 G contains SODIUM POLYSTYRENE SULFONATE : 1 G. It is listed in the Health Canada Drug Product Database under DIN 02473941, held by ODAN LABORATORIES LTD, supplied as POWDER FOR SUSPENSION for ORAL ; RECTAL administration. Health Canada currently lists it as marketed, status dated 25-Oct-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02473941 |
|---|---|
| Brand name | ODAN-SODIUM POLYSTYRENE SULFONATE |
| Generic / active ingredient | SODIUM POLYSTYRENE SULFONATE : 1 G |
| Manufacturer | ODAN LABORATORIES LTD |
| Strength | 1 G |
| Dosage form | POWDER FOR SUSPENSION |
| Route of administration | ORAL ; RECTAL |
| Schedule | Prescription |
| ATC code | V03AE01 POLYSTYRENE SULPHONATE |
| AHFS class | 40:18.18 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 25-Oct-2018 |
| Original market date | 2018-12-11 00:00:00 |
How is it stored and handled?
Room Temperature
What can be used instead?
Other Canadian products sharing ATC code V03AE01 POLYSTYRENE SULPHONATE. 7 of 16 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP SODIUM POLYSTYRENE SULFONATE | 1 G | POWDER FOR SUSPENSION | JAMP PHARMA CORPORATION | MARKETED | DIN 02497557 |
| KAYEXALATE | 1 G | POWDER FOR SUSPENSION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02026961 |
| ODAN-SODIUM POLYSTYRENE SULFONATE | 250 MG | SUSPENSION | ODAN LABORATORIES LTD | MARKETED | DIN 02473968 |
| RESONIUM CALCIUM | 999 MG | POWDER FOR SOLUTION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02017741 |
| SOLYSTAT | 1 G | POWDER FOR SUSPENSION | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 00755338 |
| SOLYSTAT | 250 MG | SUSPENSION | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 00769541 |
| JAMP CALCIUM POLYSTYRENE SULFONATE | 999 MG | POWDER FOR SUSPENSION | JAMP PHARMA CORPORATION | DORMANT | DIN 02502631 |
| K-EXIT POUDRE | 100 % | POWDER FOR SOLUTION | OMEGA LABORATORIES LIMITED | CANCELLED POST MARKET | DIN 00765252 |
| PHL-SODIUM POLYSTYRENE SULFONATE ORAL SUSPENSION | 250 MG | SUSPENSION | PHARMEL INC | CANCELLED POST MARKET | DIN 02261650 |
| PHL-SODIUM POLYSTYRENE SULFONATE POWDER | 94.3 MG | POWDER | PHARMEL INC | CANCELLED POST MARKET | DIN 02261677 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.